Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC is a phase 3, interventional study registered as NCT04585490 by Maximilian Diehn, with a registry enrolment figure of 48 participants, started 2021-08-25 and due to reach its primary completion in 2026-08. Interventions recorded: Durvalumab; Carboplatin; Pemetrexed; Paclitaxel; Cisplatin; AVENIO ctDNA Surveillance Kit; Tremelimumab. Conditions listed: Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc. Primary outcome: Change in ctDNA Level Following Chemotherapy. Lung eligibility wording from the registry: "Histologically- or cytologically-documented NSCLC presenting with locally-advanced, unresectable stage III disease (Version 8 of AJCC Staging Manual) or NSCLC with locoregional recurrence after previous definitive treatment". Sites: United States. No results are recorded here; the registry entry is the source.